129101-54-8 Rivastigmine tartrate AKSci J10584
 
 
Loading Please Wait...
  J10584    AKSci Reference Standard
Rivastigmine tartrate, >98% (HPLC)
 
N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate
IDENTITY
CAS Number:129101-54-8
MDL Number:MFCD03700731
MF:C14H22N2O2.C4H6O6
MW:400.42
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>98% (HPLC)
Physical Form (at 20°C):Solid
Melting Point:115-128°C
Optical Rotation:+4.7° (c=5, EtOH)
Long-Term Storage:Store long-term in a cool, dry place
DOT/IATA TRANSPORT INFORMATION
UN #:UN2811
Hazard Class:6.1; Poison
Packing Group:III
A hazmat fee may apply depending on the amount ordered, as indicated in the list of package sizes.

BIOLOGICAL INFO
Solubility:EtOH; MeOH
Application(s):Cholinesterase inhibitor

REVIEW
 Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

REFERENCES
[1]Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25.
[2] Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8.
[3] Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004 Jul;26(7):980-90.
[4] Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 1998;11(4):211-216.

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of March 26, 2023

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS Request COA

⚠️
These chemical products are for research and development use only. They are not for diagnostic, therapeutic, cosmetic, or human and animal uses. They are not sold to individuals. Additional restrictions may apply.

New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information.


CATEGORIES
 APIs and Bioactives > AChR Agonists, Alzheimer's


PubChem